Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Global experience with new extended-depth-of-focus intraocular lens

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Enlarged-Depth-of-Focus II

Session Date/Time: Monday 12/09/2016 | 16:00-18:00

Paper Time: 16:06

Venue: Hall C3

First Author: : J.Vukich USA

Co Author(s): :                        

Abstract Details


To demonstrate visual performance and patient satisfaction with contralateral implantation of an aspheric monofocal IOL in the dominant eye and an extended depth of focus intraocular lens in the non-dominant eye.


Multiple clinics throughout the world.


Prospective, multicenter, open-label clinical study. 102 patients have been implanted and three-month outcomes are presented on 63 patients. Binocular uncorrected distance, intermediate and near visual acuities (UDVA, UIVA & UNVA) and patient satisfaction were evaluated. Mean ± standard deviation visual acuity is reported in logMAR. Interim results are presented here and additional patients and longer-term follow up data will be presented.


The mean binocular UDVA, UIVA and UNVA were -0.03 ± 0.14 (20/18), 0.03 ± 0.10 (20/21) and 0.17 ± 0.11 (20/29) at 3 months. At 3 months, 100%, 100% and 95.3% of patients achieved 20/40 or better binocularly at distance, intermediate and near respectively. 96.7% of patients said they would do the procedure again. Overall the average rating for glare and halos were 1.5 ± 1.1 and 1.1 ± 1.5 out of a maximum rating of 5 (very severe).


Contralateral implantation of the small aperture IC-8 IOL and aspheric monofocal IOL shows excellent visual performance and patient satisfaction at three-months following implantation.

Financial Disclosure:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous